mindGear

The US Food and Drug Administration (FDA) has granted approval for Caputron Medical’s mindGear headset for the treatment of serious psychiatric diseases such as depression, insomnia and anxiety.

After more than five years of therapy optimisation and clinical testing, mindGear was approved to provide patients immediate and lasting relief through a drug-free therapy.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

For many patients with psychiatric diseases, drug-based treatments do not provide sufficient relief and cause severe side effects.

Caputron’s mindGear is a small battery powered device that connects to the head via special hydroPod electrodes. It is a neuromodulation therapy that gently activates the brain in a way that encourages endogenous healing.

Caputron Medical US sales vice-president Jennifer Higgins said: “mindGear represents a major advance in the wearable tech and digital health space.

“Portable, personal, and customisable, mindGear is both a consumer and medical neuromodulation device.”

“Portable, personal, and customisable, mindGear is both a consumer and medical neuromodulation device.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The device secured FDA clearance for indications, including depression, insomnia and anxiety with further clinical trials for new indications ongoing.

mindGear, which can be used in almost any environment, is available in the US with a prescription.

Caputron Medical CEO Robin Azzam said: “Neuromodulation, also called electroceuticals, is the fastest growing area in the treatment of neurological and psychiatric disorders.

“mindGear further establishes Caputron Medical as a leader in the personalised therapy space with a handheld and personalised device.”

The company is a distributor of consumer, clinical and research neurostimulation technology and is aimed at improving the field through the development and distribution of new therapeutics and through the support of research devices.


Image: mindGear is a gentle, drug-free treatment cleared by the FDA for depression, anxiety and insomnia. Photo: courtesy of Caputron Medical.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact